[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-epilepsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-epilepsy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,47,78,96,156,184,210,239,261,282,308,331,360,381,412,441,462,484,503,525,550,577],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643647","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-100643647",false,"NCT07594119","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 2","Inclusion Criteria:\n\n1. Age 18 - 75\n2. BMI 18-45 kg\u002Fm2\n3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1\n4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis\n5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs\n6. Ability to keep accurate daily focal seizure records using an e-diary\n\nExclusion Criteria:\n\n1. Known hypersensitivity or prior exposure to RAP-219.\n2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur\n3. Anticipated need for surgery during the study period\n4. Medical history of any of the following:\n\n   1. generalized epilepsy\n   2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type\n   3. psychogenic nonepileptic seizure (PNES)\n   4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).\n   5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).\n5. Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product","ALL","18 Years","75 Years",{"count":21,"type":22},312,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.",[28,29,30],"Focal Seizure","Epilepsy","Focal Epilepsy",[32,33],"Focal Preserved Consciousness","Focal Impaired Consciousness","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2029-09",{"name":44,"class":45},"Rapport Therapeutics Inc.","INDUSTRY",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100641069","high-density-flexible-ecog-for-epilepsy-surgery---a-single-arm-ect-100641069","NCT07656857","High-density Flexible ECoG for Epilepsy Surgery - A Single-Arm ECT","Precision Resection of the Epileptogenic Zone Using Intraoperative Subdural High-density Flexible Electrocorticography - A Single-Arm Trial With an External Historical Control Cohort","PRECISE","Inclusion Criteria:\n\n1. Aged 3 to 60 years.\n2. Diagnosed with drug-resistant epilepsy, defined as persistent seizures despite treatment with two or more appropriately selected, adequately dosed, and adequately tried antiseizure medications.\n3. Diagnosed with focal epilepsy after a standard presurgical epilepsy evaluation and considered suitable for resective epilepsy surgery.\n4. Preoperative Mini-Mental State Examination (MMSE) score ≥ 24.\n5. Able to provide written informed consent, or written informed consent provided by a legal guardian when applicable.\n\nExclusion Criteria:\n\n1. Suspected mesial temporal lobe epilepsy after multidisciplinary presurgical evaluation.\n2. History of any previous neurosurgical craniotomy before epilepsy surgery.\n3. Severe psychiatric, cognitive, or psychological disorder that prevents participation in the study or completion of follow-up.\n4. Contraindication to surgery.","3 Years","60 Years",{"count":58,"type":22},85,[60],"NA","What's the clinical value of high-density flexible electrocorticography (ECoG) for guiding the resection of epileptogenic zone (EZ) in epilepsy surgery?",[30],[64,65],"Epilepsy surgery","High-density Flexible Electrocorticography","NOT_YET_RECRUITING","2026-06-15",{"date":69,"type":38},"2026-06-18",{"date":71,"type":22},"2026-07-01",{"date":73,"type":22},"2028-12-31",{"name":75,"class":76},"Beijing Tiantan Hospital","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":14,"acronym":83,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":26,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":95,"locationsCount":46},"100636299","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-focus-1-100636299","NCT07563881","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1","FOCUS 1",{"count":85,"type":22},333,[25],[28,29,30],[32,33],"2026-06-12",{"date":91,"type":38},"2026-06-16",{"date":93,"type":38},"2026-06-05",{"date":42,"type":22},{"name":44,"class":45},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100640275","spatial-scene-recognition-memory-in-epilepsy-surgery-100640275","NCT07580183","Spatial Scene Recognition Memory in Epilepsy Surgery","Investigations of Spatial Recognition Memory to Improve Cognitive Outcomes in Epilepsy Surgery","Inclusion Criteria:\n\n* Age 18 years or older\n* For Aims I and III: Diagnosis of focal epilepsy or temporal lobe lesion; patients undergoing evaluation for or having undergone epilepsy surgery\n* For Aim II: Healthy adult participants\n* Full-Scale IQ ≥ 70\n* English proficiency sufficient to understand and complete the task\n* For Aim I: Enrolled in or eligible for Emory University epilepsy surgery research registry\n* For Aim III: Undergoing clinically indicated stereoelectroencephalography (SEEG) at UC Davis Medical Center\n* Able to provide informed consent (or for Aim I retrospective component, prior consent in Emory registry)\n\nExclusion Criteria:\n\n* Full-Scale IQ \\\u003C 70\n* Inability to provide informed consent\n* For Aim III: Age \\> 55 years\n* For Aim II: History of neurological or psychiatric disorder (as applicable per study protocol)",true,"55 Years",{"count":106,"type":22},620,[60],"This study investigates the anatomical and physiological basis of spatial scene recognition memory in patients with temporal lobe epilepsy and temporal lobe lesions. Standard neuropsychological tests are insensitive to important memory deficits experienced by patients, particularly in spatial\u002Fscene memory, recollective experience, and familiarity processing. Using a validated virtual tour paradigm, the study examines how familiarity-based recognition and recall of spatial scenes relate to specific brain structures. In Aim I, a large cohort of patients with varied temporal lobe lesions at Emory University undergoes the virtual tour task with voxel-based lesion-symptom mapping to localize necessary brain regions. In Aim II, scalp event-related potentials and eye tracking in healthy participants at UC Davis characterize the temporal dynamics and lateralization of scene recognition. In Aim III, intracranial EEG recordings (including local field potentials and single-unit activity) in epilepsy surgery patients at UC Davis determine the precise network dynamics underlying spatial scene familiarity and recall. The long-term goal is to improve the prediction and prevention of cognitive morbidity from epilepsy surgery by providing a more complete model of spatial recognition memory circuits.",[30,110,111,112,113,114,115,116,117,118,119,120],"Temporal Lobe Epilepsy","Medically Refractory Epilepsy","Memory Disorders","Epilepsy Comorbidities","Epilepsy Intractable","Epilepsy Surgery","Epilepsy, Temporal Lobe","Memory Deficits","Memory Disorder, Spatial","Memory Dysfunction","Spatial Perception",[122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145],"spatial memory","recognition memory","familiarity","recollection","neural circuits of memory","phenomenology of memory","scene memory","virtual tour","epilepsy surgery","SEEG","stereo-electroencephalography","lesion-symptom mapping","network-symptom mapping","cognitive electrophysiology","event-related potentials","intracranial EEG","iEEG","parahippocampal gyrus","perirhinal cortex","hippocampus","tetrodes","deja vu","neuropsychology","consciousness","2026-05-06",{"date":148,"type":38},"2026-05-12",{"date":150,"type":38},"2024-07-01",{"date":152,"type":22},"2030-06-30",{"name":154,"class":76},"University of California, Davis",2,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100526296","phase-2-a-study-to-determine-if-bhv-7000-is-effective-and-safe-in-adults-with-refractory-focal-onset-epilepsy-100526296","NCT06132893","A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy","A Phase 2\u002F3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy","RISE 2","Key Inclusion Criteria:\n\n1. Male and Female participants 18 to 75 years of age at time of consent.\n2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.\n\n   a. Focal seizures i. Focal aware seizures with clinically observable signs and\u002For symptoms ii. Focal impaired awareness seizures iii. Focal to bilateral tonic-clonic seizures\n3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.\n4. Ability to keep accurate seizure diaries\n5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total\n\nKey Exclusion Criteria:\n\n1. History of status epilepticus (convulsive status epilepticus for \\> 5 minutes or focal status epilepticus with impaired consciousness for \\> 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.\n2. History of repetitive\u002Fcluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase.\n3. Resection neurosurgery for seizures \\\u003C4 months prior to the screening visit.\n4. Radiosurgery performed \\\u003C2 years prior to the screening visit.\n5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms.\n6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and\u002For confound the interpretation of safety or efficacy data from the study, as judged by the Investigator",{"count":165,"type":22},390,[167,25],"PHASE2","The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.",[30],[30,29,171,172,173],"Seizure","Refractory Epilepsy","Partial Epilepsy","2026-04-30",{"date":176,"type":38},"2026-05-01",{"date":178,"type":38},"2024-03-14",{"date":180,"type":22},"2026-12",{"name":182,"class":45},"Biohaven Therapeutics Ltd.",124,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100631770","phase-3-double-blind-randomized-clinical-trial-evaluating-the-efficacy-and-safety-of-vormatrigine-in-adults-with-focal-seizures-100631770","NCT07505004","Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures","A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures","POWER2","Inclusion Criteria:\n\n* Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017).\n* Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and\u002For in consultation with the medical monitor.\n* Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1.\n* Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period.\n* Seizure diary must be completed for ≥80% days in the Observation Period.\n\nExclusion Criteria:\n\n* Participant has had any of the following within the 12-month period preceding trial entry:\n\n  1. evidence of experiencing pseudo or psychogenic seizures\n  2. cluster seizures where the individual seizures cannot be counted\n  3. an episode of convulsive status epilepticus requiring hospitalization and intubation\n  4. seizures secondary to illicit drug or alcohol use\n* Seizures secondary to ongoing infection, neoplasia, demyelinating disease, progressive degenerative disease, metabolic illness deemed progressive, progressive structural lesion or encephalopathy.\n* Previously documented EEG which shows any pattern not consistent with focal etiology of seizures.\n* Planned epilepsy surgery during the course of the clinical trial.\n* History of any of the following:\n\n  1. neurosurgery for seizures \\\u003C1 year prior to enrollment\n  2. radiosurgery \\\u003C2 years prior to enrollment\n  3. neurostimulator placed \\\u003C1 year prior to Screening\n  4. neurostimulator placed \\>1 year prior to Screening but settings have not been stable for at least 2 months prior to Screening\n* Active suicidal plan\u002Fintent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt, as confirmed by C-SSRS.\n* Has any significant ongoing disease, disorder, laboratory abnormalities, alcohol or drug abuse or dependence, environmental factor, or ongoing or recent history of any psychiatric, medical, or surgical condition.\n* Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 3 years are excluded.\n* History or presence of uncontrolled cardiac diseases including conduction and structural abnormalities.\n* Total bilirubin value \\>1.5×ULN; an ALT or AST value \\>3×ULN.\n* History of or active HIV infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active hepatitis B or hepatitis C infection, as determined by relevant screening assessments.\n* Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene or cell therapy.\n* Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.\n* Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to screening.\n* Significant allergic reaction to an ASM(s), including dermatological (e.g. Stevens-Johnson syndrome), hematological, or organ toxicity reactions. Severe reactions do not include simple maculopapular eruption and allergic rhinitis.\n* Is pregnant or breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or prior to end of study visit.\n* Previous exposure to vormatrigine or known hypersensitivity to any component used in the vormatrigine formulation.","85 Years",{"count":194,"type":22},300,[25],"A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)",[30],[199],"focal epilepsy","2026-03-26",{"date":202,"type":38},"2026-04-01",{"date":204,"type":38},"2026-01-29",{"date":206,"type":22},"2027-05",{"name":208,"class":45},"Praxis Precision Medicines",7,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":77},"100593877","optimizing-therapy-in-epilepsy-using-seizure-forecasts-via-eeg-and-wearables-100593877","NCT07012148","Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables","FORESITE (FOREcasting Seizures to Initiate ThErapy): Optimizing Management of Drug-Resistant Epilepsy Using Seizure Forecasts Via Subscalp EEG and Wearables","FORESITE","Inclusion Criteria:\n\nSubjects enrolled in this study must have epilepsy involving the temporal lobe and will have undergone video-EEG monitoring within the past 3 years, and will have met the following criteria:\n\n* Focal epilepsy, including complex partial, and secondarily generalized seizures, including:\n\n  * disabling seizure (i.e. involving loss of awareness, motor control, speech, or other essential functions) counts at least 2 per month on average over the preceding 3 months, established by verbal history or caregiver report.\n  * For 3 months prior to enrollment, subject's AED dosages have been stable (less than a 25% change in dosage) and subject has had at least two seizures per month, on average, with a seizure-free interval not to exceed 60 days. Seizures must be separated by a minimum of four hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.\n* With the exception of epilepsy, subject must be medically and neurologically stable.\n* Age 18 to 75.\n* Ability and willingness to provide informed consent and participate in the study protocol. Subject is able to interpret and to respond, in accordance with the study protocol, to the advisory indicators provided by the device.\n* Subject has seizures that are distinct, stereotypical events that can be reliably counted by the subject or caregiver, and have a distinct EEG pattern that can be recorded using subscalp EEG over the frontotemporal head region, established by video-EEG monitoring.\n* Subject can reasonably be expected to maintain a seizure diary alone or with the assistance of a competent individual.\n* Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.\n* Subject's seizure focus, based upon clinical semiology, scalp EEG, intracranial electroencephalographic (iEEG) findings, and\u002For neuroimaging, demonstrate consistent involvement of the temporal lobe with their EEG seizure pattern.\n* Subject speaks and reads English.\n* Subject has no reason to anticipate requiring a magnetic resonance imaging (MRI) evaluation within the next two years.\n* Subject has EEG documentation of ictal events consistent with his or her predominant current seizure type.\n* Subject's anatomy will permit implantation of the UNEEG SubQ device in the opinion of the study's neurosurgeon.\n* Female subjects have a negative pregnancy test, have no plans to become pregnant, and use effective contraception during the study.\n\nExclusion Criteria:\n\n* For 3 months prior to enrollment, subject's AED dosages have not been stable (greater than 25% change in dosage), or subject has had more than 30 disabling seizures per month, on average, or more than 10 seizure days per month, on average.\n* Subject needs to have magnetic resonance imaging during the study period.\n* Subject has a substance abuse history (alcohol, prescription, or illicit medications) within the preceding two years.\n* Subject participated in another drug or device trial within the preceding 30 days.\n* Subject has been hospitalized for a psychiatric condition within the preceding two years or has had a history of psychosis within the preceding two years (excluding post-ictal psychosis).\n* Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, brain stimulator, or other medical device that would interfere with the UNEEG device. This includes, but is not limited to, direct brain neurostimulators, spinal cord stimulators, and cochlear implants. Vagus nerve stimulators are not expected to interfere with the subscalp EEG device and will be permitted, as long as stimulation parameters can be reasonably expected to remain stable (25% or less change in amplitude) throughout the study.\n* Subject has experienced unprovoked status epilepticus.\n* Subject has had therapeutic surgery to treat epilepsy that may interfere with electrode placement in the judgement of the neurosurgeon.\n* Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.\n* Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable. Blood tests to evaluate platelet and bleeding disorder issues will be obtained prior to enrollment.\n* Subject is otherwise ineligible for cranial surgery, or the Investigators identify other medical or psychosocial factors that would counter indicate participation in the study.\n* Subject is pregnant or intends to become pregnant during the study period.\n* Subject has a known diagnosis of psychogenic nonepileptic seizures (PNES)\n* Female subject is pregnant or plans to become pregnant.",{"count":219,"type":22},12,[60],"The purpose of this study is to evaluate the safety and feasibility of using seizure forecasts based on subscalp EEG.",[30,223,224],"Generalized Seizure","Drug Refractory Epilepsy",[226,227,228,229],"complex partial seizure","UNEEG","seizure forecasting","Subscalp EEG","2026-03-18",{"date":232,"type":38},"2026-03-19",{"date":234,"type":38},"2026-01-20",{"date":236,"type":22},"2029-12",{"name":238,"class":76},"Mayo Clinic",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":77},"100550951","thalamic-recordings-in-children-undergoing-seeg-100550951","NCT06453759","Thalamic Recordings in Children Undergoing SEEG","TRICS","Inclusion Criteria:\n\n1. All children undergoing SEEG as part of their pre-surgical evaluation at GOSH\n2. Participants\u002Fparents\u002Flegal guardian provide informed consent for inclusion\n\nExclusion Criteria:\n\n1\\) Lack of informed consent","2 Years","20 Years",{"count":249,"type":22},30,[60],"Stereoelectroencephalography (SEEG) forms a key part of the pre-surgical evaluation in children who may be candidates for epilepsy surgery. It can help delineate the location of the putative epileptogenic zone, guiding further treatments including resective, disconnective and ablative epilepsy surgery techniques. However, less than 35% of children undergoing SEEG end up becoming seizure free following further treatment.\n\nOpen and closed loop stimulation of thalamic nuclei via deep brain stimulation (DBS) and responsive neurostimulation (RNS) are emerging treatment options for epilepsy. Thalamic target nuclei vary between studies and there are currently no gold standard personalised methods for choosing a target. This stems from the limited systematic neurophysiological recordings from thalamic nuclei; investigators currently do not understand the ictal and interictal thalamic signatures of involvement in epilepsy and do not understand how functional connectivity can be altered within and between patients.\n\nIn this prospective study, the investigators aim to recruit 30 patients undergoing SEEG as part of their pre-surgical evaluation for drug resistant epilepsy at Great Ormond Street Hospital over a period of 3 years. Once recruited, the investigators will target 3 nuclei bilaterally in each patient - the anterior, centromedian and pulvinar nuclei - using additional SEEG electrodes. Following clinical recording, the investigators will conduct two stimulation experiments, the first using single pulse electrical stimulation to measure effective connectivity between the thalamus and cortical regions and the second to study the effects of simulated DBS currents on cortical local field potential signatures.\n\nThis study will lay the foundation for a personalised approach to thalamic neuromodulation for drug-resistant epilepsy by identifying neurophysiological biomarkers of thalamic involvement in epilepsy, paving the way for closed loop neuromodulation strategies that aim to optimise response using these biomarkers.",[30],{"date":254,"type":38},"2026-02-02",{"date":256,"type":38},"2025-09-01",{"date":258,"type":22},"2028-12",{"name":260,"class":76},"Great Ormond Street Hospital for Children NHS Foundation Trust",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":268,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":77},"100491037","study-of-transcranial-direct-current-stimulation-to-treat-epilepsy-100491037","NCT05673915","Study of Transcranial Direct Current Stimulation to Treat Epilepsy","Pilot Study of Transcranial Direct Current Stimulation (tDCS) to Treat Epilepsy","Inclusion Criteria\n\n* Clinical diagnosis of generalized onset or focal epilepsy or sleep-related epileptic encephalopathy.\n* Estimated to have at least 2 countable seizures per month or spike-wave index ≥50%.\n* Has not had control with at least 2 anti-seizure medicines.\n* Able to maintain a constant medication for duration of the study (rescue meds allowed).\n* Subject or legally authorized representative is able to understand consent and keep a seizure diary in English.\n\nExclusion Criteria:\n\n* A disease likely to progress over course of the study.\n* Psychogenic non-epileptic seizures.\n* Suicide attempt or psychiatric hospitalization past 2 years.\n* A skin condition interfering with scalp electrodes or allergy to silver.\n* Women will verify not pregnant, and if applicable, have a serum pregnancy test.\n* Implanted devices (e.g. pacemakers)-except VNS, which is allowed.","6 Years",{"count":249,"type":22},[60],"The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.",[30,273,274],"Generalized Onset Epilepsy","Sleep-related Epileptic Encephalopathy","2026-01-26",{"date":277,"type":38},"2026-01-28",{"date":279,"type":38},"2023-04-12",{"date":180,"type":22},{"name":238,"class":76},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":209},"100609809","phase-2-a-long-term-study-of-the-safety-and-effectiveness-of-rap-219-in-adults-with-focal-onset-seizures-100609809","NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","70 Years",{"count":249,"type":22},[167],"This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[30,29,294,171,28,295],"Refractory Focal Epilepsy","Focal Onset Seizure",[297,29,298,299],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":302,"type":38},"2026-01-23",{"date":304,"type":38},"2025-12-15",{"date":306,"type":22},"2028-02-03",{"name":44,"class":45},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":17,"minAge":268,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":4},"100617457","phase-2-efficacy-of-probenecid-on-cluster-seizures-during-anti-seizure-medication-withdrawal-in-presurgical-focal-epilepsy-video-eeg-monitoring-100617457","NCT07318870","Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring","PROBCLUSTER","Inclusion Criteria:\n\n* Patients between 6 and 50 years old\n* weighting \\> 20 kg\n* With focal seizures epilepsy\n* Requiring video-EEG recording in Epilepsy Monitoring Units (EMU) for the presurgical evaluation of a focal epilepsy, with planned ASM withdrawal in order to precipitate seizure occurrence\n* Able to take an oral therapy\n* Ability to record the patient \\> 12 hours after the second seizure of the cluster\n* Having received informed information about the study and having signed a consent form to participate in the study. Written consent of both holders of parental authority for minor patients.\n\nExclusion Criteria:\n\n* Hypersensitivity to PBN or to any of the excipients (Microcrystalline cellulose, Hypromellose, Sodium carboxymethylamidon, Colloidal anhydrous silica, Magnesium stearate)\n* Impaired renal function (creatinine clearance \\\u003C 50 mL\u002Fmin)\n* Lithiasis diathesis\n* Treatment by the following drugs: penicillins cephalosporins, acetylsalicylic acid, methotrexate, acetaminophen, naproxen, indomethacin, ketoprofen, meclofenamate, lorazepam, rifampicin, acyclovir, ganciclovir and zidovudine, sulfonamide, dyprophylline\n* Acute gout attack\n* Hyperuricemia secondary to cancer chemotherapy, radiotherapy or myeloproliferative neoplasia\n* Primary hyperuricemia due to overproduction of uric acid.\n* Pregnant or breast-feeding woman\n* Patient benefiting from legal protection\n\nSecondary exclusion criteria (before randomization) :\n\n\\- Patient not randomized: Not experiencing at least 2 seizures lasting less than 10 minutes in 6 hours or less period (defining a SC) during the video-EEG monitoring period OR having no seizure recorded before the cluster.\n\nPatients secondarily excluded will be excluded before randomization and will be replaced.","50 Years",{"count":317,"type":22},600,[167],"ProbCluster trial aims at making the proof of concept of antiseizure efficacy of the old antigout PBN in SC, in which Panx1 involvement is relevant on SC pathophysiology and in which efficient therapies are still lacking. The trial will be performed on patients with focal epilepsy in presurgical evaluation undergoing video-EEG monitoring, a setting characterized by a high risk of SC and an efficient video-EEG monitoring of seizures, reducing the risk of erroneous report based on patient home assessment. PBN is a good candidate for a repurposing in epilepsy, due to its brain penetration allowing Panx1 in situ blockade and of its good security profile. The repurposing process allows a faster, safer and cheaper development.",[30],"2025-12-19",{"date":323,"type":38},"2026-01-06",{"date":325,"type":22},"2026-01",{"date":327,"type":22},"2029-02",{"name":329,"class":330},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":77},"100531850","evaluation-of-new-flexible-high-density-intra-operative-ecog-electrodes-for-epilepsy-surgery--epigrid--100531850","NCT06205160","Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery. ( EpiGrid )","The EpiGrid Study Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery","EpiGrid","Inclusion Criteria:\n\n* Age ≥18 years at the time of enrolment\n* Lesional epilepsy (incl. secondary mesial temporal sclerosis) that is considered a candidate for intra-operative high-density grid recordings (incl. patients who underwent sEEG preceding resective surgery)\n* Provided informed consent for study participation by the subject\n\nExclusion Criteria:\n\n* Occipital lesion\n* Surgeries involving a primary mesial temporal lesion, a disconnection, or hemispherectomy.\n* Planned ioECoG recordings during fully awake surgery and\u002For functional recordings\n* Use of anticoagulants that cannot be discontinued during the perioperative period, or a factor XIII deficiency or any other haematological disease\n* Active participation in another investigational device study\n* Any other condition that in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study.\n* Insufficient understanding of Dutch language.",{"count":219,"type":22},[60],"The objective of this prospective interventional monocentric clinical investigation is to evaluate the feasibility and performance of the flexible high-density SOFT ECoG electrode grids, manufactured by Neurosoft Bioelectronics SA (test device; TD), in comparison to regular high-density electrode grids (ADTech, CE-marked) (control device; CD) routinely used at the investigation site during epilepsy surgery.\n\nSubjects will undergo ≥ 2 additional intracranial recordings pre- and post-resection with the TD next to the standard recordings with the CD during ECoG-tailored epilepsy surgery.",[30,343],"Intraoperative Monitoring",[345,346,347,348,130,349,350],"intra-operative electrocorticography","HFO","epileptic biomarkers","high frequency oscillations","flexible ECoG","subdural electrode","2025-12-09",{"date":353,"type":38},"2025-12-10",{"date":355,"type":38},"2025-01-01",{"date":357,"type":22},"2027-03",{"name":359,"class":45},"Neurosoft Bioelectronics SA",{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":77},"100611306","phase-2-an-open-label-study-to-evaluate-safety-tolerability-and-efficacy-of-cb03-154-in-subjects-diagnosed-with-epilepsy-100611306","NCT07238868","An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy","A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed With Epilepsy","Inclusion Criteria:\n\n* 1\\. The subject must be properly informed of the nature and risks of the study and give informed consent in writing, prior to entering the study.\n\n  2\\. Subject must have successfully completed the DBP and have not terminated early from Study CB03-154-EP201, met all eligibility requirements, and had no important protocol deviations (in the opinion of the sponsor) or AEs (in the opinion of the investigator) that would preclude the subject's entry into the long-term extension study, and judged to be efficacious based on the blinded data review (in the opinion of the investigator).\n\n  3\\. In the opinion of the investigator, the subject is able to understand verbal and written instructions and will adhere to all study schedules and requirements.\n\n  4\\. Subject is able to keep accurate seizure diaries.\n\nExclusion Criteria:\n\n\\- 1. Subject met any of the withdrawal criteria while in Study CB03-154-EP201. 2. Subject has any medical condition, personal circumstance, or ongoing AE (from Study CB03-154-EP201) that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study, or prevents adherence to the protocol.\n\n3\\. Subject is planning to enter a clinical study with a different investigational drug or planning to use any experimental device for treatment of epilepsy during the study and until 28 days after completion of this study.",{"count":368,"type":22},144,[167],"CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.",[30],"2025-11-16",{"date":374,"type":38},"2025-11-20",{"date":376,"type":38},"2025-08-14",{"date":378,"type":22},"2029-06",{"name":380,"class":45},"Shanghai Zhimeng Biopharma, Inc.",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":192,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":408,"leadSponsor":410,"locationsCount":77},"100607801","phase-4-butylphthalide-for-cognitive-impairment-in-elderly-patients-with-focal-epilepsy-100607801","NCT07193277","Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy","Safety and Efficacy of Butylphthalide Soft Capsules for Cognitive Impairment Comorbid With Focal Epilepsy in Elderly Patients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Age 60-85 years (inclusive)\n* Diagnosed with focal epilepsy according to ILAE 2025 latest classification standards, with disease duration ≥2 years\n* Currently receiving stable anti-seizure medication (ASM) treatment for ≥3 months, with good seizure control (monthly seizure frequency ≤4 times in the past 3 months)\n* Cognitive impairment: Montreal Cognitive Assessment (MoCA) score 18-25 points (inclusive)\n* Basic Chinese language comprehension and expression ability, able to cooperate with neuropsychological testing\n* Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\n* Diagnosed with various types of dementia (including Alzheimer's disease, vascular dementia, etc.)\n* Clear history of stroke with corresponding lesions on neuroimaging, or severe white matter lesions on brain MRI\n* Other neurological diseases that may cause cognitive impairment (traumatic brain injury, encephalitis, hydrocephalus, etc.)\n* Systemic diseases that may cause cognitive impairment (severe cardiac, hepatic, renal dysfunction, endocrine diseases, etc.)\n* Current severe depression or other psychiatric diseases affecting cognitive assessment\n* History of alcohol dependence, drug abuse, or other substance use affecting cognitive function\n* Allergy to butylphthalide or its excipients\n* Participation in other drug clinical trials within 30 days\n* Other conditions deemed inappropriate for participation by investigators",{"count":389,"type":22},220,[391],"PHASE4","This is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of butylphthalide soft capsules for treating cognitive impairment in elderly patients with focal epilepsy.\n\nStudy Population: 220 elderly patients (60-85 years) with focal epilepsy and mild to moderate cognitive impairment (Montreal Cognitive Assessment score 18-25).\n\nIntervention: Participants will be randomly assigned 1:1 to receive either butylphthalide soft capsules (0.2g three times daily) or matching placebo for 48 weeks, while continuing their stable anti-seizure medication regimen.\n\nPrimary Outcome: Change in Montreal Cognitive Assessment (MoCA) total score from baseline to 48 weeks.\n\nSecondary Outcomes: Changes in neuropsychological tests (Trail Making Test, Digit Span, Rey Auditory Verbal Learning Test), seizure control measures, functional status (Activities of Daily Living, Quality of Life in Epilepsy), and exploratory neurobiological markers.\n\nThis study addresses an important unmet medical need, as current epilepsy treatments focus primarily on seizure control but lack effective interventions for epilepsy-associated cognitive impairment. Butylphthalide, a neuroprotective agent approved for acute ischemic stroke in China, has shown promise in other cognitive disorders and may benefit this patient population through its multiple neuroprotective mechanisms.",[30,394],"Cognitive Impairment",[396,30,394,397,398,399,400,401,402,403],"Butylphthalide","Elderly","MoCA","Neuroprotection","Randomized Controlled Trial","Double-blind","Placebo-controlled","Multicenter","2025-09-18",{"date":406,"type":38},"2025-09-25",{"date":256,"type":38},{"date":409,"type":22},"2028-09-01",{"name":411,"class":76},"First Affiliated Hospital of Wenzhou Medical University",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":427,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":77},"100412627","multi-level-approach-of-brain-activity-using-intracranial-electrodes-in-epileptic-patients-100412627","NCT04653012","Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic Patients","EpiMicro","Inclusion Criteria:\n\n* Patients with focal drug-resistant epilepsy\n* Patients who undergo a presurgical evaluation with intracranial electrodes in the videoEEG unit of the Neurology department at the Pitié-Salpêtrière hospital.\n* Patients who have been informed and provided written informed consent to take part in the study\n\nExclusion Criteria:\n\n* Contraindication for an intracranial investigation (with macro-electrodes) : intercurrent infectious syndrome, decompensated associated pathology (cardiac, pulmonary, renal, hepatic), patient with increased risk of infection (ex: under immunosuppressive therapy)\n* Pregnant or parturient woman\n* Breastfeeding woman\n* Minor person or legally protected adult (tutelage, legal guardianship, maintenance of justice)",{"count":420,"type":22},50,[60],"The main goal of this project is to study the mechanisms of epileptic activities using intracranial macro and micro electrodes in epileptic patients undergoing pre-surgical investigation.\n\nThe recordings will also be used to study physiological mechanisms like sleep and different cognitive functions.",[30,424,425,426],"Electrodes, Implanted","Cognitive Function","Neurophysiology",[428,429,430],"Microelectrodes","Seizures","EEG","2025-09-02",{"date":433,"type":38},"2025-09-08",{"date":435,"type":38},"2021-02-28",{"date":437,"type":22},"2031-02-27",{"name":439,"class":440},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":77},"100500287","sleep-architecture--cognition-in-focal-epilepsy-100500287","NCT05794295","Sleep Architecture & Cognition in Focal Epilepsy","Inclusion Criteria:\n\n* Age 18 - 40 years of age\n* Focal Epilepsy\n* Capacity to fully cooperate and follow directions\n* no other significant neurological disorders which could affect cognition\n\nExclusion Criteria:\n\n* Current use of any medications that can significantly affect cognition\n* No severe sleep apnea","40 Years",{"count":449,"type":22},40,[60],"Focal Epilepsy (FE) patients and healthy controls will wear an actigraph at home for one week and a home sleep study device at home for one night. Participants will then undergo two nights of testing (at least one week apart) at California Sleep Solutions (CSS) in Sacramento, CA. During the overnight stays, participants will have EEG leads placed and possibly a headband. They will undergo cognitive testing before they go to sleep and again in the morning. During one night of testing, sounds will be played in the room (acoustic stimulation). The sounds should not wake the participants.",[30],[29],"2025-07-16",{"date":456,"type":38},"2025-07-18",{"date":458,"type":38},"2025-01-24",{"date":460,"type":22},"2028-06",{"name":154,"class":76},{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":77},"100514688","breathing-rescue-for-sudep-prevention-100514688","NCT05981755","Breathing Rescue for SUDEP Prevention","Breathing Rescue for SUDEP Prevention (BreatheS)","BreatheS","Inclusion Criteria:\n\n* diagnosis of intractable focal epilepsy\n* admitted to the Epilepsy Monitoring Unit (EMU) at Memorial Hermann-Texas Medical Center for intracranial subdural strips, grids, or depth electrode placement study (invasive video-EEG)\n\nExclusion Criteria:\n\n* respiratory, cardiac or cerebrovascular disease\n* pregnancy\n* prisoners",{"count":471,"type":22},100,[60],"The purpose of this study is to precisely delineate human brain networks that modulate respiration and identify specific brain areas and stimulation techniques that can be used to prevent seizure-induced breathing failure.",[30],"2025-06-13",{"date":477,"type":38},"2025-06-18",{"date":479,"type":38},"2023-07-31",{"date":481,"type":22},"2028-06-30",{"name":483,"class":76},"The University of Texas Health Science Center, Houston",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":370,"conditions":494,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100563177","phase-2-a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-cb03-154-in-adult-patients-with-focal-epilepsy-100563177","NCT06612775","A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 as Adjunctive Therapy in Focal Epilepsy","Inclusion Criteria:\n\n1. Ability of the subjects or his\u002Fher authorized representative be fully informed of the nature and risks of the study and give informed consent in writing prior to entering the study.\n2. Male and female aged 18 to 70 years, inclusive.\n3. 18.0 kg\u002Fm2 ≤BMI ≤ 34.0 kg\u002Fm2.\n4. Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy \\[ILAE\\] Classification of Epilepsy (2017).\n5. Prior neuroimaging within the last 5 years and documentation are available to rule out progressive structural central nervous system abnormalities at the time of the diagnosis of epilepsy.\n6. Treatment with a stable dose of 1 to 3 allowable current AEDs for at least one month prior to screening, during baseline, and throughout the duration of the DBP.\n7. Prior to screening and during baseline period, subjects must have at least 6 focal seizures without status epilepticus, with or without focal to bilateral tonic-clonic.\n8. If a female, must be:\n\n   * Postmenopausal, defined as amenorrhea for at least 12 months, and confirmed by blood follicle stimulating hormone (FSH) at Screening, OR\n   * Surgically sterile with a documented hysterectomy, partial hysterectomy, bilateral oophorectomy, or bilateral tubal ligation at least 6 months prior to Screening, OR\n   * If of child-bearing potential, heterosexually active females with male partners must be using an acceptable and highly effective method of contraception at least one menstrual cycle before first study drug administration and continuing until at least 3 months after the last dose of the study drug. If a female subject is abstinent, she must agree to use an acceptable and highly effective form of birth control as above once she becomes heterosexually active during the study.\n9. If a female of child-bearing potential, must have a negative pregnancy test result at Screening and Check-in.\n10. If a male, if heterosexually sexually active with a female partner of child-bearing potential and has not had a vasectomy, must agree to use a highly effective method of contraception and deemed appropriate by the Investigator and must not donate sperm during the study and for 3 months after the last dose of study drug.\n11. Able to keep accurate seizure diaries.\n\nExclusion Criteria:\n\n1. Subject has had documented previous EEGs indicating other patterns of epilepsy besides the focal epilepsy prior to dosing the study drug.\n2. Subject has seizures secondary to drugs or alcohol use, ongoing infection, metabolic diseases or progressive central nervous system diseases or lesions at the investigator's assessments.\n3. Subject has the history of pseudo seizures, conversion disorders, or other non-epileptic seizure conditions, or other non-epileptic ictal events that could be confused with seizures at the investigator's discretion and\u002For EEG evidence.\n4. Subject has the presence or previous history of Lennox-Gastaut syndrome, some other related syndrome or evidence of both focal and generalized epilepsy at investigator's decisions.\n5. Subject has the history of status epilepticus within 6 months prior to screening.\n6. Subject has only uncountably repetitive seizures occurring within 6 months prior to screening.\n7. Subject has the history of neurosurgery for seizures \\\u003C1 year prior to enrolment, or radiosurgery \\\u003C2 years prior to enrolment. Subjects has the implantment and activation of vagus nerve stimulation (VNS), deep brain stimulation (DBS), or other neurostimulation for epilepsy treatment \\\u003C1 year prior to enrolment, or with stimulation parameters that have been stable for \\\u003C3 months prior to enrolment, or with anticipated left battery lifetime shorter than trial duration.\n8. Subject has any of the following findings will be excluded:\n\n   * A history or family history of unexplained syncope;\n   * A history of presence of long QT syndrome; QTcF \\> 450 msec prior to first dose of the study drug; a family history of long QT syndromes or sudden death of unknown cause;\n   * Bundle branch blocks or atrioventricular or other conduction abnormalities that are clinically significant according to the Investigator and\u002For with a PR interval ≥220ms, or HR\\\u003C50bpm at rest in ECGs or vital signs, prior to first dose of the study drug;\n   * A history of venous thrombosis, or a history or presence of medical conditions indicating unresolved high risks of thrombophilia or hypercoagulability including but not limited to protein C deficiency, protein S deficiency, antithrombin deficiency, antiphospholipid syndrome, Budd-Chiari syndrome, myeloproliferative neoplasm including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), autoimmune diseases (especially systemic lupus erythematosus (SLE) or antiphospholipid syndrome or vasculitis), nephrotic syndrome, paroxysmal nocturnal hemoglobinuria, uncured malignancy, unstoppable estrogen containing oral or injection contraception or hormone replacement therapy, postpartum period within 2 months, or other medical conditions at the investigator and the medical monitor's judgements;\n   * Venous ultrasound examinations on bilateral lower extremes indicating DVT;\n   * \\> 2.0 Upper limit of normal (ULN) of blood D-Dimer, or \\>1.5 Upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), amylase (AMY) prior to first dose of the study drug. If subject has \\>ULN of above laboratory tests that does not meet the exclusion limit at screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase at the investigator's and\u002For the medical monitor's judgments;\n   * The estimated glomerular filtration rate (eGFR) at screening is \\\u003C60mL\u002Fmin and the calculated result of female is ×0.85.\n9. Subject has any clinically significant abnormalities on physical examination, vital signs, laboratory tests or ECG prior to first dose of the study drug which could jeopardize or would compromise the subject's safety or ability to participate in this study as deemed by the Investigator and the Medical monitor.\n10. Subject has the history or presence of significant medical or surgical condition including but not limited to cardiac, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, psychiatric disease, or history of cancer within the past 2 years, with the exception of appropriately treated basal cell or squamous cell carcinoma, or any condition which could jeopardize or would compromise the subject's safety or ability to participate in this study in the opinion of the investigator and\u002For the medical monitor at enrolment.\n11. Subject with active pathogen infections or carrier including but not limited to testing positive at Screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or syphilis.\n12. Subject has schizophrenia and other psychotic disorders, or active suicidal plan\u002Fintent in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening, or a history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt) within 2 years prior to enrolment, or more than 1 lifetime suicide attempt.\n13. Subject ever used vigabatrin without no vigabatrin-related visual field abnormalities confirmed by examination within the past 6 months at screening (concomitant use of vigabatrin is not allowed).\n14. If felbamate will be a concomitant AED during study, the subject must be on felbamate for at least 2 years, and with a stable dose for at least 2 months prior to screening and without planned changes of the dose during the study. Subject must not have a history of white blood cell (WBC) count below 3000\u002FμL (3.00 \\*109\u002FL), platelets below 75,000\u002Fmm3 (75\\*109\u002FL), liver function tests above 1.5 times the ULN, or other indication of hepatic or bone marrow dysfunction while receiving felbamate. If felbamate was ever used before, it must have been discontinued for at least 2 months prior to screening.\n15. Subject has taken other (non-AED) prescription, nonprescription, dietary (e.g., grapefruit or passion fruit), or herbal products that are potent inducers or strong or moderately inhibitors of the CYP3A4 pathway for 2 weeks prior to the baseline.\n16. Subject has received an investigational medicinal product within 3 months or within 10 half-lives of the drug (whichever is longer) or IMP of monoclonal antibodies, cytokines, growth factors, soluble receptors, other recombinant products, or fusion proteins within 6 months prior to the first dose of study drug.\n17. Subject is known allergic or hypersensitive to any of excipients of CB03-154 tablet formulation.\n18. Subject has had multiple drug allergies or a severe drug reaction to an AED(s), including dermatological, hematological, or organ toxicity reactions.\n19. Subject has a history of indicated alcohol abuse or drug abuse at the investigator's decision during the 6 months prior to screening. Subject tested positive for substance abuse at screening or check-in.\n20. Female subject who is pregnant or in the postpartum period within 2 months or breastfeeding.",{"count":492,"type":22},180,[167],[30],"2024-09-22",{"date":497,"type":38},"2024-09-25",{"date":499,"type":22},"2024-09",{"date":501,"type":22},"2026-09",{"name":380,"class":45},{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":103,"sex":17,"minAge":55,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":77},"100438238","diffusion-mri-methods-to-minimize-postoperative-deficits-in-pediatric-epilepsy-surgery-100438238","NCT04986683","Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery","Novel DWI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery","Inclusion Criteria:\n\n1. Subjects with drug-resistant focal epilepsy\n\n   1\\. Age 3-19 years. 2. Planned two-stage epilepsy surgery with subdural electrodes.\n2. Healthy control subjects 1. Age 5-19 years. 2. No cognitive, motor, and\u002For language impairment or clinical elevations on a measure of behavioral problems. 3. Brain MRI interpreted as normal.\n\nExclusion Criteria:\n\nFor all subjects:\n\n1\\. History of prematurity or perinatal hypoxic-ischemic event. 2. Hemiplegia on preoperative neurological examination by pediatric neurologists. 3. Dysmorphic features suggestive of a clinical syndrome. 4. Diagnosis of any pervasive developmental or psychiatric condition which clearly predates the onset of seizures, including autism spectrum disorder, tic disorders, obsessive-compulsive disorder. 5. MRI abnormalities showing massive brain malformation and other extensive lesions that likely destroyed the contralateral tracts and severely affected i) spatial normalization accuracy in advanced normalization tools (ANTs), mutual information (MI) between native T1- MRI of Geodesic SyN transform and template T1-MRI \\\u003C mean-3\\*standard deviation of MI in the healthy control group and ii) parcellation accuracy in surface-matching-based deformable registration, target registration error (TRE) of fine tetrahedra mesh between native T1- MRI brain surface and template T1-MRI brain surface \\> mean-3\\*standard deviation of TRE in the healthy control group. 6. History of claustrophobia. 7. Unsuccessful MRI showing head motion \\> 2 mm in DWMRI (i.e., voxel size of DWMRI) which is evaluated by NIH TORTOISE DWMRI motion artifact correction package. 8. Subject who cannot speak English.","19 Years",{"count":512,"type":22},60,[60],"This project will test the accuracy of a novel diffusion-weighted magnetic resonance imaging (DWMRI) approach using a deep convolutional neural network (DCNN) to predict an optimal resection margin for pediatric epilepsy surgery objectively. Its primary goal is to minimize surgical risk probability (i.e., functional deficit) and maximize surgical benefit probability (i.e., seizure freedom) by precisely localizing eloquent white matter pathways in children and adolescents with drug-resistant focal epilepsy. This new imaging approach, which will acquire a DWMRI scan before pediatric epilepsy surgery in about 10 minutes without contrast administration (and also without sedation even in young children), can be readily applied to improve preoperative benefit-risk evaluation for pediatric epilepsy surgery in the future. The investigators will also study how the advanced DWMRI-DCNN connectome approach can detect complex signs of brain neuronal reorganization that help improve neurological and cognitive outcomes following pediatric epilepsy surgery. This new imaging approach could benefit targeted interventions in the future to minimize neurocognitive deficits in affected children. All enrolled subjects will undergo advanced brain MRI and neurocognitive evaluation to achieve these goals. The findings of this project will not guide any clinical decision-making or clinical intervention until the studied approach is thoroughly validated.",[30],"2024-07-22",{"date":518,"type":38},"2024-07-23",{"date":520,"type":38},"2021-08-01",{"date":522,"type":22},"2026-06-30",{"name":524,"class":76},"Wayne State University",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":532,"targetDuration":534,"studyType":535,"phases":4,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":548,"locationsCount":77},"100532224","cognitive-impairment-in-drug-resistant-and-drug-responsive-focal-cryptogenic-epilepsy-100532224","NCT06210022","Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy","Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy: a Longitudinal Observational Study","Inclusion Criteria:\n\n* Inclusion criteria for all study subjects:\n\n  * monolingual native Italian speakers;\n  * age between 18-60 years;\n  * normal or corrected-to-normal visual acuity;\n  * oral and written informed consent to study participation.\n  * if assuming psychotropic drugs (i.e., benzodiazepines, antipsychotics, antidepressants), they should be at stable dosage for more than 4 weeks.\n* Inclusion criteria for DRE patients:\n\n  * diagnosis of focal cryptogenic epilepsy;\n  * previous failure of at least 2 anti-seizure medication (ASM at adequate dose;\n  * at least 3 seizures in the last 2 months; • available brain MRI (\\\u003C5 years).\n* Inclusion criteria for DSE patients:\n\n  * diagnosis of focal cryptogenic epilepsy;\n  * seizure control obtained after not more than 2 ASM;\n  * seizure freedom for at least 6 months;\n  * available brain MRI (\\\u003C5 years).\n* Inclusion criteria for NDE patients:\n\n  * new diagnosis of focal cryptogenic epilepsy (\\\u003C3 months)\n  * not more than 1 ASM tested\n  * available brain MRI (\\\u003C3 months)\n\nExclusion Criteria:\n\n* Age\\> 60 years;\n* Documented developmental delay;\n* Evidence of focal abnormalities at neuroimaging (except of hippocampal sclerosis);\n* Neurological degenerative conditions;\n* history of other systemic (including systemic neoplasms in the last 3 years and abnormal hepatorenal functions), neurologic, psychiatric diseases, head injury, cardiovascular events, and cerebrovascular alterations;\n* alcohol and\u002For psychotropic drugs abuse",{"count":533,"type":22},130,"12 Months","OBSERVATIONAL","This is a national monocentric (San Raffaele Hospital - OSR, Via Olgettina, 60, 20132 Milan, Italy) observational low-risk-intervention study, prospective and multiparametric (clinical, EEG, neuropsychological evaluations) study.\n\nPatients with a diagnosis of DRE and DSE will be screened to evaluate their eligibility. They will undergo clinical and cognitive assessments in addition to 32channel EEG at baseline (T0). DRE patients will also undergo clinical and cognitive assessments, and 32-channel EEG at 6 months (T1), and 12 months (T2). Patients newly diagnosed with focal cryptogenic epilepsy (NDE) will undergo clinical and cognitive assessments, and 32-channel EEG at baseline (T0), at 6 months (T1), and 12 months (T2).\n\nHigh-definition EEG will be performed to investigate patterns of cortical sources and functional connectivity alteration specific to DRE and DSE and to explore their prognostic value. Longitudinal EEGs will be acquired to explore the evolution of EEG patterns.\n\nCognitive evaluation will be performed by an experienced neuropsychologist. At baseline, DRE, DSE, and NDE patients will undergo a screening and a comprehensive cognitive battery in order to define performance differences among groups. The DRE and NDE group only will perform the same neuropsychological assessment at month 6 and 12 for monitoring the potential progression of cognitive and\u002For behavioural disturbances in these patients.",[29,30],[539,540,541],"epilepsy","focal cryptogenic epilepsy","drug resistant epilepsy","2024-06-20",{"date":544,"type":38},"2024-06-24",{"date":542,"type":38},{"date":547,"type":22},"2027-03-01",{"name":549,"class":76},"IRCCS San Raffaele",{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":11,"sex":17,"minAge":558,"maxAge":18,"enrollmentInfo":559,"targetDuration":4,"studyType":535,"phases":4,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":576},"100447002","optimized-volumetry-in-radiology-interest-in-pediatric-brain-mri-in-the-exploration-of-focal-epilepsy-100447002","NCT05100771","Optimized Volumetry in Radiology: Interest in Pediatric Brain MRI in the Exploration of Focal Epilepsy","Volumétrie Optimisée en Radiologie : intérêt en IRM Cérébrale pédiatrique Dans l'Exploration de l'épilepsie Focale","ORACLE","Inclusion Criteria:\n\n* Patient aged 1-18 years\n* Referred or followed by a pediatrician for epilepsy with focal onset\n* Requiring brain MRI as part of the work-up\n\nExclusion Criteria:\n\n* Opposition of the child and\u002For parent to data processing\n* MRI not interpretable\n* Clinical and epileptic data not available or not specifying focus","1 Year",{"count":560,"type":22},240,"Multicentre cross-sectional study with prospective recruitment comparing the detection rate of lesions on brain MRI without and with quantitative volumetry and T1 relaxometry information during the management of children with suspected focal epilepsy.",[30],[564,565,566],"Brain MRI","Radiology","Pediatry","2024-06-03",{"date":569,"type":38},"2024-06-04",{"date":571,"type":38},"2022-03-14",{"date":573,"type":22},"2025-03",{"name":575,"class":76},"University Hospital, Tours",5,{"id":578,"slug":579,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":585,"enrollmentInfo":586,"targetDuration":4,"studyType":535,"phases":4,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":601},"100335231","atlas-of-human-cognition-by-seeg-mapcog-seeg-100335231","NCT03644732","Atlas of Human Cognition by SEEG (MAPCOG-SEEG)","Atlas of Human Cognition by SEEG","MAPCOG-SEEG","Inclusion Criteria:\n\n* Drug-resistant focal epilepsy\n* Justified SEEG exploration in the context of presurgical assessment of epilepsy\n* Written non-opposition to study participation\n* Intellectual capacities compatible with the compliance in the cognitive tasks\n\nExclusion Criteria:\n\n* Major Patient undergoing a legal protection measure or patient deprived of liberty as a result of a judicial or administrative decision\n* Impossibility of collecting information on exposure (recent arrival in France, foreign language, etc.)\n* Pregnant women (Contraindication to SEEG exploration)","65 Years",{"count":587,"type":22},200,"The main objective of MAPCOG\\_SEEG is to create a database including brain recordings of cognition performed in clinical routine in patients during the pre-surgical SEEG assessment. This aims to be able to propose the first atlas of human cognition with a high temporal and spatial resolution.",[172,30],[591],"Cognition","2024-03-18",{"date":594,"type":38},"2024-03-19",{"date":596,"type":38},"2018-04-05",{"date":598,"type":22},"2030-09",{"name":600,"class":76},"University Hospital, Grenoble",4]